Osugacestat

The properties of the blood-brain barrier serve a vital protective role, but they also keep drugs from reaching the organ. Big pharmaceutical companies have been making deals for technologies that could help them get their molecules through this protective membrane and now GSK is joining in, striking up an alliance that gives it a new way to shuttle drugs into the brain to treat neurodegeneration. The agreement announced Monday gives GSK access to a platform technology developed by ABL Bio. Specific diseases covered by the pact were not disclosed. The deal kicks off with GSK paying South Korea-based ABL £38.5 million (about $49.1 million) up front. The drug delivery approach of ABL is based on Grabody, a platform technology that develops bispecific antibodies, proteins engineered to bind to two targets. For treating brain diseases, the bispecific antibodies from Grabody contain a domain designed to bind to insulin-like growth factor 1 receptor (IGF1R), a receptor that transports proteins across the blood-brain barrier. The other binding domain is designed to go after the desired target for treating a brain disorder. Sponsored Post Changes in Nurse Staffing Answer Clinician Demands The ongoing nursing shortage facilitates high turnover rates since nurses know they won’t have difficulties finding new jobs. In order to retain and attract staff, it’s in a facility’s best interest to understand what nurses want. By Tomasz Rezik GSK and ABL aren’t disclosing the brain targets they’re pursuing. But the agreement covers multiple programs for novel targets that could be treated with various therapeutic modalities. For example, they say an ABL brain drug could be used to deliver genetic medicines to the brain, such as a small-interfering RNA drugs or antisense oligonucleotides. ABL’s most advanced brain program is a Parkinson’s disease drug candidate in development under a partnership with Sanofi. The brain target of this preclinical drug, ABL301, is alpha-synuclein. While that protein is also the target of other Parkinson’s drug candidates, ABL contends the bispecific approach of its drug could more efficiently target alpha-synuclein compared to traditional monoclonal antibodies. Under GSK’s deal, ABL will transfer to the pharma giant technology and know-how related to the Grabody-B platform. GSK will take on responsibility for preclinical and clinical development, along with manufacturing and potential commercialization. Depending on the progress of the research, ABL could receive up to £2.075 billion (about $2.6 billion) in milestone payments, plus royalties if any drugs resulting from collaboration reach the market. “Many of the most promising new therapies are antibodies, which cannot efficiently reach the brain without a shuttle to get them across the [blood-brain barrier],” Christopher Austin, senior vice president of research technologies, GSK, said in a prepared statement. “This agreement reflects our commitment to innovative platform technologies to overcome the BBB and thus open entirely new opportunities for treating these devastating diseases, an important component of our emerging pipeline.” presented by Sponsored Post What Are the Best Medical Coding Outsourcing Companies? Outsourcing your medical coding can help ensure a healthy revenue cycle. Discover the best medical coding outsourcing companies and find the right one for you. By Global Healthcare Resources GSK already has clinical-stage Alzheimer’s programs from a partnership with Alector that began 2021. Latozinemab (formerly AL001) is in Phase 3 testing; Alector has said it expects preliminary data by the end of 2025. AL101 (also known as GSK4527226) is in Phase 2. Both drugs are monoclonal antibodies intended to reduce degradation of progranulin, a protein that regulates immune activity in the brain. The targeting of a receptor to deliver a therapy across the blood-brain barrier gives GSK another way to potentially treat neurodegeneration, but it’s not alone in this approach, called receptor-mediated transcytosis. The platform technology of Aliada Therapeutics engineers antibodies to target the transferrin and CD98 receptors to transport molecules across the blood-brain barrier. Similar to ABL, Aliada said its technology can be applied to multiple types of therapeutic cargos, such as enzymes, proteins, and oligonucleotides. With the biotech’s lead program in early clinical development for Alzheimer’s disease, AbbVie last year agreed to pay $1.4 billion to acquire Aliada. ABL’s research also spans Grabody drugs in development for cancer. A partnership with I-Mab is developing PD-L1- and claudin 18.2-targeting drugs; both programs are in Phase 1 for solid tumors. The most advanced ABL program is ABL001 (also known as tovecimig), a VEGF-targeting drug in late-stage clinical development for biliary tract cancer among other cancer indications under a partnership with Compass Therapeutics.

Integration of AL102 and IM-1021 completed Topline data for Phase 3 RINGSIDE trial of AL102 expected in second half of 2025 IM-1021 and IM-3050 IND submissions expected in first quarter of 2025 BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the first quarter ended March 31, 2024, and provided a business update. “Immunome continues to build momentum. We have completed the integration of AL102 and are executing activities necessary for regulatory submissions,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer. “We have also completed the integration of IM-1021 and are advancing that program and IM-3050 towards clinical trials.” Dr. Siegall continued, “In addition, we are working internally to design and develop additional next-generation ADC technology. Those efforts are complemented by our ongoing business development efforts, which seek to identify and procure high-quality technologies and clinical programs. Both our internal and external efforts are focused on expanding Immunome’s pipeline with additional programs that have first-in-class or best-in-class potential and can improve the lives of cancer patients.” Pipeline Highlights The purchase of AL101 and AL102 from Ayala Pharmaceuticals closed on March 25, 2024. Full enrollment for the Phase 3 RINGSIDE Part B study of AL102 for the treatment of desmoid tumors was completed in February 2024. Immunome expects to report topline data for RINGSIDE Part B in the second half of 2025. In parallel, Immunome continues to perform additional manufacturing and pharmacology work required to support a new drug application filing for AL102. Immunome anticipates submitting INDs for two preclinical candidates in the first quarter of 2025: IM-1021, a ROR1 ADC, and IM-3050, a FAP-targeted RLT. First Quarter 2024 Financial Results As of March 31, 2024, cash, cash equivalents and marketable securities totaled $309.7 million. Immunome’s current cash runway is expected to extend into 2026. Research and development expenses for the quarter ended March 31, 2024 were $15.4 million, including stock-based compensation costs of $0.4 million. In-process research and development expenses for the quarter ended March 31, 2024 were $112.0 million. These expenses were related to Immunome’s acquisition of AL101 and AL102 from Ayala Pharmaceuticals, Inc. and the exclusive license of IM-1021 and related ADC platform technology from Zentalis Pharmaceuticals, Inc., both of which closed in the quarter ended March 31, 2024. General and administrative expenses for the quarter ended March 31, 2024 were $6.0 million, including stock-based compensation expense of $1.8 million. Immunome reported a net loss of $129.5 million, or basic and diluted net loss per share attributable to common stockholders of $2.51, for the quarter ended March 31, 2024. About Immunome, Inc. Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including small molecules, ADCs, and RLTs. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets. For more information, visit or follow us on Twitter and LinkedIn. Cautionary Statement Regarding Forward-Looking Statements Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). We use words such as “may,” “could,” “potential,” “will,” “plan,” “believe,” “expect,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. These forward-looking statements include, but are not limited to, Immunome’s expectation to report topline data for the ongoing Phase 3 RINGSIDE Part B trial of AL102 in the second half of 2025; Immunome’s expected timeline for submitting INDs for IM-3050 and IM-1021 in the first quarter of 2025; Immunome’s expected cash runway; Immunome’s ability to expand its pipeline through both internal and external efforts; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Such forward-looking statements are based on Immunome’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the risk that Immunome will not be able to realize the benefits of its strategic transactions; Immunome’s ability to grow and successfully execute on its business plan, including the development and commercialization of its pipeline and integration of newly acquired assets; changes in the applicable laws or regulations; the possibility that Immunome may be adversely affected by other economic, business, and/or competitive factors; the risk that regulatory approvals for Immunome’s programs and product candidates are not obtained, are delayed or are subject to unanticipated conditions; the risk that pre-clinical data may not be predictive of clinical data; the risk that interim results of a clinical trial do not necessarily predict final results; potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the risk that Immunome’s product and development candidates fail to achieve their intended endpoints; the complexity of numerous regulatory and legal requirements that Immunome needs to comply with to operate its business; the reliance on Immunome’s management; the prior experience and successes of the Immunome’s management team not being indicative of any future success; uncertainties related to Immunome’s capital requirements and Immunome’s expected cash runway; the failure to obtain, adequately protect, maintain or enforce Immunome’s intellectual property rights; and other risks and uncertainties indicated from time to time described in Immunome’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 26, 2024, in ARS Pharma’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, being filed with the SEC today, and in Immunome’s other filings with the SEC. Immunome cautions that the foregoing list of factors is not exclusive and not to place undue reliance upon any forward-looking statements which speak only as of the date made. Moreover, Immunome operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Except as required by law, Immunome does not undertake any obligation to update publicly any forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in their expectations. Immunome, Inc. Condensed Consolidated Balance Sheets (Unaudited; In thousands) March 31, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 269,723 $ 98,679 Marketable securities 39,983 39,463 Prepaid expenses and other current assets 3,620 6,561 Total current assets 313,326 144,703 Property and equipment, net 4,302 2,073 Operating right-of-use assets 1,458 1,564 Restricted cash 100 100 Other long-term assets 568 100 Total assets $ 319,754 $ 148,540 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 7,179 $ 3,311 Accrued expenses and other current liabilities 10,844 8,025 Deferred revenue, current 12,745 10,493 Total current liabilities 30,768 21,829 Deferred revenue, non-current 2,208 5,489 Operating lease liabilities, net of current portion 1,206 1,340 Total liabilities 34,182 28,658 Stockholders’ equity: Preferred stock — — Common stock 6 4 Additional paid-in capital 637,861 342,663 Accumulated other comprehensive income 4 22 Accumulated deficit (352,299 ) (222,807 ) Total stockholders’ equity 285,572 119,882 Total liabilities and stockholders’ equity $ 319,754 $ 148,540 Immunome, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited; In thousands, except share and per share amounts) Three Months Ended March 31, 2024 2023 Collaboration revenue $ 1,029 $ 2,364 Operating expenses: In-process research and development 111,954 — Research and development(1) 15,369 3,913 General and administrative(1) 6,005 2,922 Total operating expenses 133,328 6,835 Loss from operations (132,299 ) (4,471 ) Interest income 2,807 201 Net loss $ (129,492 ) $ (4,270 ) Net loss per share, basic and diluted $ (2.51 ) $ (0.35 ) Weighted-average shares outstanding, basic and diluted 51,544,383 12,182,478 Comprehensive loss Net loss $ (129,492 ) $ (4,270 ) Unrealized loss on marketable securities (18 ) — Comprehensive loss $ (129,510 ) $ (4,270 ) (1) Amounts include non-cash, stock-based compensation expense as follows (in thousands): Three Months Ended March 31, 2024 2023 Research and development $ 383 $ 430 General and administrative 1,776 794 Total share-based compensation expense $ 2,159 $ 1,224